about
sameAs
Aspirin resistance in ischaemic heart diseasePlatelet aggregation and P-selectin levels during exercise treadmill test in patients with ischaemic heart diseaseAspirin failure course during exercise and its connection with soluble CD40LGastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.The risk for syncope and presyncope during surgery in surgeons and nurses.The choice of surgical specialization by medical students and their syncopal history.Aptamers: the emerging class of future anticoagulation for vascular disease.Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the WoEvaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis.MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study.Plasma adiponectin concentration in relation to severity of coronary atherosclerosis and cardiovascular risk factors in middle-aged men.Sex steroids concentrations in relation to bone mineral density in men with coronary atherosclerosis.Genetic testing in antiplatelet therapy - not effective for perioperative bleeding.Relation between heavy metals and left ventricular diastolic function in patients with coronary artery disease.No-reflow and platelet reactivity in diabetic patients with ST-segment elevation myocardial infarction: is there a link?The in vitro effects of niacin on platelet biomarkers in human volunteers.Fatal sepsis and systemic inflammatory response syndrome after off-label prasugrel: a case report.Predicting Bleeding Risk by Platelet Function Testing in Patients Undergoing Heart Surgery.Anticoagulant and anti-platelet activity of polyphenolic-polysaccharide preparation isolated from the medicinal plant Erigeron canadensis L.Androgen receptor polymorphism and platelet reactivity in healthy menLeczenie antyagregacyjne u pacjentów z ostrym zespołem wieńcowym — zalecenia dla zespołów ratownictwa medycznego. Stanowisko ekspertówBaseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery diseaseEffect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarctionResponse to Dual Antiplatelet Therapy Does Not Impact Bleeding Risks in Patients Undergoing Oral Surgery after Acute Coronary SyndromesRelationship between high on aspirin platelet reactivity and oxidative stress in coronary artery by-pass grafted patientsAspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarctionExcessive long-term platelet inhibition with prasugrel or ticagrelor and risk of infection: another hidden danger?Changes in response to clopidogrel therapy in patients after percutaneous coronary interventions as assessed by different platelet function testsDistribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian populationDoes Arterial Hypertension Affect Plasma Levels of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Stable Coronary Artery Disease? A Preliminary Study
P50
Q28173903-0AC50575-4539-4886-A433-A15C835309BAQ28208785-DCD92475-793C-455A-872E-E64BEDFACEF3Q28219169-7EE984D1-13F0-47C6-B1B1-8BECDBA381B3Q30655618-A45D5328-973C-4F02-B999-676D132FC5C9Q33160299-0E445A9F-E437-4029-898A-9BFDA150A1B3Q33162342-805925C0-3D30-4673-9D56-F6754F18B8E6Q33389174-FB03CCEA-620A-427B-826C-114126844B1EQ37378896-33FA3A64-E9E9-4BFA-BF5A-0C16FF41B227Q38515336-7EA09232-627E-4E87-AE1C-88DF84F08742Q41099760-2A7760FC-BF39-4319-A70C-14539BBFCFB7Q46368034-70DF1304-C2A1-48B1-8996-03211CBBD4A5Q46964328-56334F9A-59EC-451B-B059-65CEC572C835Q47160727-C1640386-0A18-4B95-8685-0A4A7E122663Q47291657-86A4373D-3BD5-459C-A731-DF835DE851B0Q49463261-A23BBC36-0085-4BAD-92D3-B6A85FF1BB7EQ50042941-D76C249B-46B1-4B7E-ADE3-CCD8AA7C1992Q50357189-EBAD38E1-6DAA-49A4-BF2E-6DEC800E37FBQ50435870-208D5E1B-E1EC-4A8C-9F38-869ED91DBD16Q53281599-C2DE2A0D-4058-4DBD-85DD-99415D38E54EQ57599371-B0A9FFC0-FDFF-4864-BF99-EE45A67E21CAQ58819323-ECA95A49-056E-45A9-BBE6-134D19C16745Q81607383-CB2B6B0E-1D2C-42CE-9993-44873B1CF7BCQ84058068-25E24BF5-BE14-4195-B180-45D58B0E1A5DQ85521475-FA170DBE-DAD7-40F7-A0FF-FFE66B95B765Q86602680-D1D72122-3191-45FA-97EF-E63F5C4082C1Q87036764-EB39780D-55C6-49D1-943A-4CA3C5905B8AQ87318563-D7B683A3-6AD1-493D-A7B8-5773668B1AF3Q88147988-BB470116-C5DC-4C71-AA14-CF5CA9E891D8Q91509788-3F224082-F7C6-445F-BA03-EF432496989DQ91532162-8682AEDF-46B3-4983-A1EA-24319E4634AF
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Wiktor Kuliczkowski
@ast
Wiktor Kuliczkowski
@en
Wiktor Kuliczkowski
@es
Wiktor Kuliczkowski
@nl
Wiktor Kuliczkowski
@pl
Wiktor Kuliczkowski
@sl
type
label
Wiktor Kuliczkowski
@ast
Wiktor Kuliczkowski
@en
Wiktor Kuliczkowski
@es
Wiktor Kuliczkowski
@nl
Wiktor Kuliczkowski
@pl
Wiktor Kuliczkowski
@sl
altLabel
Wiktor Kazimierz Kuliczkowski
@pl
prefLabel
Wiktor Kuliczkowski
@ast
Wiktor Kuliczkowski
@en
Wiktor Kuliczkowski
@es
Wiktor Kuliczkowski
@nl
Wiktor Kuliczkowski
@pl
Wiktor Kuliczkowski
@sl
P106
P1153
6602758163
P21
P214
66149717305010950292
P31
P3124
P496
0000-0001-6284-0820
P734
P7859
viaf-66149717305010950292